US5648254A
(en)
*
|
1988-01-15 |
1997-07-15 |
Zymogenetics, Inc. |
Co-expression in eukaryotic cells
|
US5037743A
(en)
*
|
1988-08-05 |
1991-08-06 |
Zymogenetics, Inc. |
BAR1 secretion signal
|
US6210948B1
(en)
|
1992-06-09 |
2001-04-03 |
The University Of British Columbia |
Expression and secretion of heterologous polypeptides from caulobacter
|
US5914254A
(en)
*
|
1993-08-02 |
1999-06-22 |
Celtrix Pharmaceuticals, Inc. |
Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
|
US5563046A
(en)
*
|
1993-08-02 |
1996-10-08 |
Celtrix Pharmaceuticals, Inc. |
Fusion polypeptides and proteins
|
US6911528B1
(en)
|
1994-12-02 |
2005-06-28 |
The Johns Hopkins University School Of Medicine |
Hedgehog-derived polypeptides
|
US6214794B1
(en)
|
1994-12-02 |
2001-04-10 |
The Johns Hopkins University School Of Medicine |
Method of using hedgehog polypeptides to regulate neuronal cell growth
|
US6281332B1
(en)
*
|
1994-12-02 |
2001-08-28 |
The Johns Hopkins University School Of Medicine |
Hedgehog-derived polypeptides
|
US6057091A
(en)
*
|
1994-12-02 |
2000-05-02 |
The Johns Hopkins University School Of Medicine |
Method of identifying compounds affecting hedgehog cholesterol transfer
|
ZA974809B
(en)
*
|
1996-05-31 |
1998-01-23 |
Akzo Nobel Nv |
Live attenuated RTX-producing bacteria of the family pasteurellaceae.
|
PT1632574E
(pt)
|
1996-10-16 |
2011-03-17 |
Zymogenetics Inc |
Homólogos do factor de crescimento fibroblástico
|
WO1998023763A1
(en)
*
|
1996-11-29 |
1998-06-04 |
The General Hospital Corporation |
Heterologous antigens in live cell v. cholerae strains
|
KR20010005701A
(ko)
|
1997-03-24 |
2001-01-15 |
리스 데브라 케이. |
모틸린 상동체
|
CA2331199C
(en)
|
1998-06-10 |
2012-10-23 |
Markus Sakari Kauppinen |
Isolated mannanases for use in treating cellulosic or synthetic fibers
|
NZ510744A
(en)
|
1998-09-23 |
2003-02-28 |
Zymogenetics Inc |
Cytokine receptor zalpha11
|
WO2000034474A2
(en)
|
1998-12-07 |
2000-06-15 |
Zymogenetics, Inc. |
Growth factor homolog zvegf3
|
DE60042617D1
(de)
|
1999-01-07 |
2009-09-03 |
Zymogenetics Inc |
Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
|
US7833529B1
(en)
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
CA2261186A1
(en)
|
1999-02-19 |
2000-08-19 |
University Of British Columbia |
Expression and secretion of heterologous polypeptides from freshwater caulobacter
|
DK1165791T3
(da)
|
1999-03-09 |
2008-02-11 |
Zymogenetics Inc |
Humant cytokin som zalpha-receptor-ligand og anvendelse deraf
|
US6664386B1
(en)
|
1999-04-08 |
2003-12-16 |
The Research Foundation Of State University Of New York |
System for efficient secretion of recombinant proteins
|
WO2001004304A1
(en)
|
1999-07-07 |
2001-01-18 |
Zymogenetics, Inc. |
Human cytokine receptor
|
US7304151B2
(en)
|
1999-12-17 |
2007-12-04 |
University Of Guelph |
Modified leukotoxin gene and protein
|
EP1242600B1
(de)
|
1999-12-23 |
2010-03-03 |
ZymoGenetics, Inc. |
Zytokin zcyt018
|
EP1749888B1
(de)
|
2000-04-05 |
2010-01-27 |
ZymoGenetics, Inc. |
Löslicher Zytokinrezeptor zalpfa11
|
DK1325115T3
(en)
|
2000-06-26 |
2016-11-21 |
Zymogenetics Inc |
CYTOKINRECEPTOR ZCYTOR17
|
US7863020B2
(en)
|
2000-06-28 |
2011-01-04 |
Glycofi, Inc. |
Production of sialylated N-glycans in lower eukaryotes
|
US7795002B2
(en)
*
|
2000-06-28 |
2010-09-14 |
Glycofi, Inc. |
Production of galactosylated glycoproteins in lower eukaryotes
|
WO2002002627A2
(en)
|
2000-06-30 |
2002-01-10 |
Zymogenetics, Inc. |
Interferon-like protein zcyto21
|
EP1736545A3
(de)
|
2000-08-08 |
2007-03-28 |
ZymoGenetics, Inc. |
Lösliche Zcyctor 11 Cytokinrezeptoren
|
KR100447530B1
(ko)
*
|
2001-08-14 |
2004-09-08 |
한국과학기술원 |
OmpF를 이용하여 목적 단백질을 대장균 세포외로분비생산하는 방법
|
PT2302063T
(pt)
|
2001-10-15 |
2016-07-28 |
Engeneic Molecular Delivery Pty Ltd |
Minicélulas intactas, como vetores para a transferência de adn e terapêutica genética in vitro e in vivo
|
EP1451322B1
(de)
|
2001-11-05 |
2009-09-30 |
ZymoGenetics, Inc. |
Il-21-antagonisten
|
WO2003054155A2
(en)
*
|
2001-12-19 |
2003-07-03 |
Bristol-Myers Squibb Company |
Pichia pastoris formate dehydrogenase and uses therefor
|
ATE547430T1
(de)
|
2002-01-18 |
2012-03-15 |
Zymogenetics Inc |
Multimere des cytokinrezeptors zcytor17
|
AU2003225525B2
(en)
|
2002-01-18 |
2008-07-24 |
Zymogenetics, Inc. |
Novel cytokine zcytor17 ligand
|
ES2356307T3
(es)
|
2002-04-19 |
2011-04-06 |
Zymogenetics, L.L.C. |
Procedimientos para detectar o modular la interacción de un receptor de citocina con su ligando.
|
DK1531850T3
(da)
|
2002-06-07 |
2012-06-04 |
Zymogenetics Inc |
Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere
|
WO2004078965A1
(ja)
*
|
2003-03-05 |
2004-09-16 |
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute |
大腸菌における異種蛋白質の製造方法
|
US20040241677A1
(en)
*
|
2003-05-29 |
2004-12-02 |
Lin Jeffrey S |
Techniques for automated diagnosis of cell-borne anomalies with digital optical microscope
|
ES2296423B1
(es)
*
|
2003-07-31 |
2009-03-16 |
Consejo Sup. Investig. Cientificas |
Construccion de adn para la produccion de proteinas de fusion dimericas y sus aplicaciones.
|
WO2005023862A2
(en)
|
2003-08-07 |
2005-03-17 |
Zymogenetics, Inc. |
Homogeneous preparations of il-28 and il-29
|
WO2005014028A1
(en)
|
2003-08-08 |
2005-02-17 |
Novo Nordisk A/S |
Interleukin-20 for treating and diagnosing conditions associated with neovascularisation
|
CN102516386A
(zh)
|
2003-10-10 |
2012-06-27 |
诺沃挪第克公司 |
Il-21衍生物
|
EP2633866A3
(de)
|
2003-10-17 |
2013-12-18 |
Novo Nordisk A/S |
Kombinationstherapie
|
ES2362881T3
(es)
|
2003-12-09 |
2011-07-14 |
Engeneic Molecular Delivery Pty Ltd. |
Administración génica dirigida a células de mamífero no fagocíticas a través de minicélulas intactas obtenidas de bacterias.
|
CA2558811A1
(en)
|
2004-03-08 |
2005-09-22 |
Zymogenetics, Inc. |
Dimeric fusion proteins and materials and methods for producing them
|
EP2389944A1
(de)
|
2004-07-29 |
2011-11-30 |
ZymoGenetics, L.L.C. |
Nutzung von IL-28 und IL-29 zur Behandlung von Krebs
|
EP1781784A2
(de)
|
2004-08-02 |
2007-05-09 |
BASF Plant Science GmbH |
Verfahren zur isolierung von transkriptionsterminationssequenzen
|
HUE024999T2
(en)
|
2004-08-26 |
2016-02-29 |
Engeneic Molecular Delivery Pty Ltd |
Introducing functional nucleic acids into mammalian cells with bacterial intact minicells
|
WO2006086396A2
(en)
|
2005-02-08 |
2006-08-17 |
Zymogenetics, Inc. |
Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
|
WO2006124667A2
(en)
|
2005-05-12 |
2006-11-23 |
Zymogenetics, Inc. |
Compositions and methods for modulating immune responses
|
WO2006130657A2
(en)
*
|
2005-05-31 |
2006-12-07 |
Bristol-Myers Squibb Company |
Stereoselective reduction process for the preparation of pyrrolotriazine compounds
|
US8808696B2
(en)
|
2005-08-09 |
2014-08-19 |
Ares Trading S.A. |
Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
|
JP2009507777A
(ja)
*
|
2005-08-09 |
2009-02-26 |
ザイモジェネティクス,インコーポレイティド |
TACI−Ig融合分子を用いたB細胞性腫瘍の処置方法
|
BRPI0711823A2
(pt)
*
|
2006-05-15 |
2012-01-17 |
Ares Trading Sa |
métodos para tratamento de doenças auto-imunes com uma molécula de fusão taci-ig
|
HUE033007T2
(en)
|
2006-06-23 |
2017-11-28 |
Engeneic Molecular Delivery Pty Ltd |
Targeted drug, therapeutic nucleic acid and functional nucleic acid delivery to mammalian cells via intact killed bacterial cells
|
US20080124355A1
(en)
|
2006-09-22 |
2008-05-29 |
David Gordon Bermudes |
Live bacterial vaccines for viral infection prophylaxis or treatment
|
DK2152297T3
(en)
*
|
2007-05-31 |
2015-06-01 |
Alizé Pharma SAS |
NON-acylated ghrelin AS A THERAPEUTIC AGENT IN THE TREATMENT OF METABOLIC DISEASES
|
US8318664B2
(en)
|
2007-05-31 |
2012-11-27 |
Alize Pharma Sas |
Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
|
AU2008308509B2
(en)
|
2007-10-04 |
2014-10-23 |
Zymogenetics, Inc. |
B7 family member zB7H6 and related compositions and methods
|
EP2602263B1
(de)
|
2007-11-21 |
2019-07-17 |
Roskilde Universitet |
Polypeptide mit ice-bindender Aktivität
|
WO2009080054A1
(en)
*
|
2007-12-21 |
2009-07-02 |
Ifxa A/S |
Protease inhibitor
|
NZ600205A
(en)
*
|
2008-01-25 |
2013-12-20 |
Univ Aarhus |
Selective exosite inhibition of papp-a activity against igfbp-4
|
EP2274008B1
(de)
|
2008-03-27 |
2014-02-26 |
ZymoGenetics, Inc. |
Zusammensetzungen und verfahren zur hemmung von pdgfrbeta und vegf-a
|
WO2009158696A1
(en)
|
2008-06-27 |
2009-12-30 |
Zymogenetics, Inc. |
SOLUBLE HYBRID Fcγ RECEPTORS AND RELATED METHODS
|
US20120020996A1
(en)
|
2008-08-06 |
2012-01-26 |
Jonathan Lewis Telfer |
Vaccines against clostridium difficile and methods of use
|
US8647642B2
(en)
|
2008-09-18 |
2014-02-11 |
Aviex Technologies, Llc |
Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment
|
US8241623B1
(en)
|
2009-02-09 |
2012-08-14 |
David Bermudes |
Protease sensitivity expression system
|
US8771669B1
(en)
|
2010-02-09 |
2014-07-08 |
David Gordon Bermudes |
Immunization and/or treatment of parasites and infectious agents by live bacteria
|
US9597379B1
(en)
|
2010-02-09 |
2017-03-21 |
David Gordon Bermudes |
Protease inhibitor combination with therapeutic proteins including antibodies
|
US8524220B1
(en)
|
2010-02-09 |
2013-09-03 |
David Gordon Bermudes |
Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
|
CN103168048B
(zh)
|
2010-06-09 |
2017-02-15 |
酶原遗传学有限公司 |
二聚vstm3融合蛋白和相关的组合物和方法
|
EP2670426B1
(de)
|
2011-01-31 |
2017-05-10 |
The General Hospital Corporation |
Multimodale trail-moleküle und ihre verwendungen in zelltherapien
|
EP2583975A1
(de)
*
|
2011-10-21 |
2013-04-24 |
Heinrich-Heine-Universität Düsseldorf |
Mittel und Verfahren zur Expression und Sekretion von Peptiden und Proteinen
|
EP3597764A3
(de)
|
2012-02-01 |
2020-05-06 |
SGI-DNA, Inc. |
Material und verfahren zur synthese von fehlerminimierten nukleinsäuremolekülen
|
EP3473708B1
(de)
|
2012-07-24 |
2021-01-27 |
The General Hospital Corporation |
Onkolytische virustherapie für resistente tumore
|
WO2014035474A1
(en)
|
2012-08-30 |
2014-03-06 |
The General Hospital Corporation |
Compositions and methods for treating cancer
|
AU2013312838B2
(en)
|
2012-09-04 |
2018-11-29 |
Cellectis |
Multi-chain chimeric antigen receptor and uses thereof
|
US9593339B1
(en)
|
2013-02-14 |
2017-03-14 |
David Gordon Bermudes |
Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
|
EP2990485B1
(de)
|
2013-04-25 |
2019-09-11 |
Kaneka Corporation |
Fd-kettengen oder l-kettengen zur erhöhung der sekretionsmenge des antikörpers vom fab-typ
|
FI3546572T3
(fi)
|
2013-05-13 |
2024-05-06 |
Cellectis |
Cd19-spesifinen kimeerinen antigeenireseptori ja sen käyttötapoja
|
WO2014202089A2
(en)
|
2013-06-18 |
2014-12-24 |
Roskilde Universitet |
Variants of anti-freeze polypeptides
|
EP3082834B1
(de)
|
2013-12-11 |
2020-03-11 |
The General Hospital Corporation DBA Massachusetts |
Von stammzellen abgegebener onkolytischer herpes-simplex-virus und verfahren zur behandlung von hirntumoren
|
JP2017504601A
(ja)
|
2013-12-20 |
2017-02-09 |
セレクティスCellectis |
免疫療法のためにマルチインプットシグナル感受性t細胞を操作する方法
|
US9737592B1
(en)
|
2014-02-14 |
2017-08-22 |
David Gordon Bermudes |
Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
|
WO2015140268A1
(en)
|
2014-03-19 |
2015-09-24 |
Cellectis |
Cd123 specific chimeric antigen receptors for cancer immunotherapy
|
JP2017518071A
(ja)
|
2014-05-02 |
2017-07-06 |
セレクティスCellectis |
Cs1特異的多重鎖キメラ抗原受容体
|
EP3453406B1
(de)
|
2014-07-29 |
2021-04-14 |
Cellectis |
Ror1(ntrkr1)-spezifische chimäre antigenrezeptoren für krebsimmuntherapie
|
EP3194432B1
(de)
|
2014-07-31 |
2019-04-10 |
Cellectis |
Ror1-spezifischer mehrkettiger chimärer antigenrezeptor
|
EP3699188A1
(de)
|
2014-09-04 |
2020-08-26 |
Cellectis |
5t4(tpbg)-spezifische chimäre antigenrezeptoren für die krebsimmuntherapie
|
US9616114B1
(en)
|
2014-09-18 |
2017-04-11 |
David Gordon Bermudes |
Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
|
EP3250602A1
(de)
|
2015-01-26 |
2017-12-06 |
Cellectis |
T-zellenrezeptor-knockout-manipulierte immunzellen mit an cd123 bindenden chimären antigenrezeptoren zur behandlung von rezidivierenden/refraktären akuten myeloischen lymphomen oder blastischen plasmazytoiden dendritischen zellneoplasmen
|
EP3757128A1
(de)
|
2015-04-13 |
2020-12-30 |
Pfizer Inc |
Chimäre antigenrezeptoren zum targeting des b-zell-reifungsantigens
|
US20180112006A1
(en)
|
2015-04-17 |
2018-04-26 |
The General Hospital Corporation |
Agents, systems and methods for treating cancer
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
EP3298046A1
(de)
|
2015-05-20 |
2018-03-28 |
Cellectis |
Anti-gd3-spezifische chimäre antigenrezeptoren für krebsimmuntherapie
|
AU2016321146C1
(en)
|
2015-09-08 |
2021-10-28 |
Theripion, Inc. |
ApoA-1 fusion polypeptides and related compositions and methods
|
CN108699124A
(zh)
|
2016-01-21 |
2018-10-23 |
辉瑞大药厂 |
靶向表皮生长因子受体变体iii的嵌合抗原受体
|
EP3522935A4
(de)
|
2016-10-06 |
2020-05-13 |
EnGeneIC Molecular Delivery Pty Ltd. |
Bakterielle minizellen zur freisetzung von nukleinsäureadjuvanzien und verfahren zur verwendung davon
|
WO2018073394A1
(en)
|
2016-10-19 |
2018-04-26 |
Cellectis |
Cell death inducing chimeric antigen receptors
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
WO2018136163A2
(en)
|
2016-12-09 |
2018-07-26 |
Theripion, Inc. |
Tandem apoa-1 fusion polypeptides
|
AU2018246377A1
(en)
|
2017-03-31 |
2019-10-17 |
Cellectis Sa |
Universal anti-CD22 chimeric antigen receptor engineered immune cells
|
MX2019012360A
(es)
|
2017-04-19 |
2019-11-28 |
Allogene Therapeutics Inc |
Composiciones y metodos mejorados de celulas t.
|
AU2018278321A1
(en)
|
2017-06-02 |
2019-11-21 |
Pfizer Inc. |
Chimeric antigen receptors targeting FLT3
|
CA3067914A1
(en)
|
2017-06-30 |
2019-01-03 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
SG11202000503QA
(en)
|
2017-07-20 |
2020-02-27 |
Aptevo Res & Development Llc |
Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
|
WO2019072824A1
(en)
|
2017-10-09 |
2019-04-18 |
Cellectis |
IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
|
JP7261232B2
(ja)
|
2017-11-01 |
2023-04-19 |
アロジーン セラピューティクス,インコーポレイテッド |
改変カスパーゼ-9ポリペプチドおよびその使用方法
|
SG11202005692WA
(en)
|
2017-12-20 |
2020-07-29 |
Harbour Biomed Shanghai Co Ltd |
Antibodies binding ctla-4 and uses thereof
|
US10150801B1
(en)
|
2017-12-27 |
2018-12-11 |
Imunami Laboratories Pte. Ltd. |
Recombinant polypeptides and methods of use thereof
|
CN111801346A
(zh)
|
2017-12-27 |
2020-10-20 |
免疫实验室私人有限公司 |
重组多肽及其使用方法
|
CA3089318A1
(en)
|
2018-02-01 |
2019-08-08 |
Pfizer Inc. |
Chimeric antigen receptors targeting cd70
|
CA3090032A1
(en)
|
2018-02-01 |
2019-08-08 |
Pfizer Inc. |
Antibodies specific for cd70 and their uses
|
RU2020128082A
(ru)
|
2018-03-02 |
2022-04-04 |
Аллоджен Терапьютикс, Инк. |
Индуцибельные химерные цитокиновые рецепторы
|
WO2020007593A1
(en)
|
2018-07-02 |
2020-01-09 |
Cellectis |
Chimeric antigen receptors (car)-expressing cells and combination treatment for immunotherapy of patients with relapse refractory adverse genetic risk aml
|
EP3880307A1
(de)
|
2018-11-14 |
2021-09-22 |
Fundación Pública Andaluza Progreso Y Salud |
Polynukleotid für sicherere und wirksamere immuntherapien
|
US11471497B1
(en)
|
2019-03-13 |
2022-10-18 |
David Gordon Bermudes |
Copper chelation therapeutics
|
EP4013506A1
(de)
|
2019-08-12 |
2022-06-22 |
Aptevo Research and Development LLC |
4-1bb- und ox40-bindende proteine und verwandte zusammensetzungen und verfahren, antikörper gegen 4-1bb, antikörper gegen ox40
|
EP4021512A1
(de)
|
2019-08-26 |
2022-07-06 |
Imunami Laboratories Pte. Ltd. |
Rekombinante polypeptide und verfahren zur verwendung davon
|
US10675332B1
(en)
|
2019-08-26 |
2020-06-09 |
Imunami Laboratories Pte. Ltd. |
Recombinant polypeptides and methods of use thereof
|
US20230144204A1
(en)
|
2020-03-18 |
2023-05-11 |
Numaferm Gmbh |
Fragments of hlya and uses thereof
|
EP3882260A1
(de)
*
|
2020-03-18 |
2021-09-22 |
NUMAFERM GmbH |
Fragmente von hlya und verwendungen davon
|
US10973908B1
(en)
|
2020-05-14 |
2021-04-13 |
David Gordon Bermudes |
Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
|
WO2021262081A1
(en)
|
2020-06-22 |
2021-12-30 |
Imunami Laboratories Pte. Ltd. |
Recombinant polypeptides and combinations for use in the treatment of cancer
|
KR20230040331A
(ko)
|
2020-07-21 |
2023-03-22 |
알로젠 테라퓨틱스 인코포레이티드 |
강화된 신호 전달 및 활성을 갖는 키메라 항원 수용체 및 이의 용도
|
US20240043868A1
(en)
|
2020-09-21 |
2024-02-08 |
Fundación Pública Andaluza Progreso Y Salud |
Polynucleotide for physiological expression in t-cells
|
EP4255574A1
(de)
|
2020-12-01 |
2023-10-11 |
Aptevo Research and Development LLC |
Heterodimere psma- und cd3-bindende bispezifische antikörper
|
MX2023007384A
(es)
|
2020-12-21 |
2023-07-05 |
Allogene Therapeutics Inc |
Car con puerta cd45 activado por proteasa.
|
WO2022165233A1
(en)
|
2021-01-29 |
2022-08-04 |
Allogene Therapeutics, Inc. |
KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS
|
CA3207134A1
(en)
|
2021-02-19 |
2022-08-25 |
Jeffrey A. Ledbetter |
Dnase fusion polypeptides and related compositions and methods
|
KR20230151518A
(ko)
|
2021-03-04 |
2023-11-01 |
알로젠 테라퓨틱스 인코포레이티드 |
치료 세포를 동종이계 거부반응 및 활성화 유도된 세포 사멸로부터 보호하기 위한 FasL 발현 및 FasR 유전자 녹아웃
|
WO2022194403A1
(en)
|
2021-03-18 |
2022-09-22 |
Numaferm Gmbh |
Fusion proteins comprising gg repeat sequences
|
WO2022266203A1
(en)
|
2021-06-15 |
2022-12-22 |
Allogene Therapeutics, Inc. |
Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence
|
WO2023192895A1
(en)
|
2022-03-29 |
2023-10-05 |
Allogene Therapeutics Inc. |
Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals
|
WO2024026445A1
(en)
|
2022-07-29 |
2024-02-01 |
Allogene Therapeutics Inc. |
Engineered cells with reduced gene expression to mitigate immune cell recognition
|
EP4339202A1
(de)
|
2022-09-16 |
2024-03-20 |
NUMAFERM GmbH |
Fusionsproteine mit gg-wiederholungssequenzen ii
|